Vasculitis tends to present in a systemic manner, often affecting multiple organ systems. Clinicians should consider a broad differential (possible conditions that share the same symptoms) and think about the entire person—not just at the time of diagnosis but throughout their life as they face periods of remission and relapse.…...
UNC’s Multidisciplinary Vasculitis and Connective Tissue Disease Clinic Offers Patients Team-Oriented Approach to Care
Autoimmune diseases are complicated conditions that can impact many organ systems in a patient. Typical models of care with providers spread out in different offices can lead to delays in diagnosis and slow down treatment options, while confusing patients as to who is making the decisions. At the University of…...
Introducing Our 2020-2021 VCRC-VF Fellow: Alvise Berti, MD
Dr. Berti began his work in vasculitis while he was a medical student at Vita-Salute San Raffaele University in Milan, Italy. At the time, Dr. Berti recognized that vasculitis was not very well understood, and being both curious and motivated to further explore this group of diseases, he realized that…...
Introducing Our 2020-2021 VCRC-VF Fellow: Alvise Berti, MD
Dr. Berti began his work in vasculitis while he was a medical student at Vita-Salute San Raffaele University in Milan, Italy. At the time, Dr. Berti recognized that vasculitis was not very well understood, and being both curious and motivated to further explore this group of diseases, he realized that…...
ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis
October 8. 2021 ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis ChemoCentryx announced today that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan) as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), and specifically for granulomatosis with polyangiitis…...
